OneAscent Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

OneAscent Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-452	Closed	-$325K	–	176
2023 Q2	$325K	Buy	452 +16	+4%	+$12.3K	0.15%	65
2023 Q1	$358K	Buy	436 +93	+27%	+$70.1K	0.14%	96
2022 Q4	$247K	Sell	343 -14	-4%	-$10.3K	0.12%	136
2022 Q3	$246K	Buy	+357	New	+$225K	0.13%	116
2022 Q2	–	Sell	-317	Closed	-$221K	–	220
2022 Q1	$221K	Buy	+317	New	+$201K	0.11%	187

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OneAscent Wealth Management's REGN Position: Q3 2023 in Review

OneAscent Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 452 shares — an estimated $325K sold.

OneAscent Wealth Management first reported a position in REGN in Q1 2022 and held it in 5 quarters. The position peaked at $358K in Q1 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

OneAscent Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
OneAscent Wealth Management sold 452 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $325K.
OneAscent Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 5 quarters.
OneAscent Wealth Management's Regeneron Pharmaceuticals position peaked at $358K in Q1 2023.
1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on OneAscent Wealth Management's 13F filing for Q3 2023, filed 13 Oct 2023.